The results of the Kaplan-Meier analysis and log-rank test indicated significant differences in survival rates among patients with renal cell carcinoma, uveal melanoma, and prostate adenocarcinoma according to ACE2 expression level. The gene discussed is ACE2; the disease is prostate adenocarcinoma.